Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials | SYRS Stock News
I'm PortAI, I can summarize articles.
Rege Nephro Co., Ltd. has acquired Tamibarotene-related assets from Syros Pharmaceuticals to enhance its clinical trial operations in the U.S. The acquisition, completed on February 26, 2025, includes clinical and non-clinical data, contracts with a contract manufacturing organization, and the active pharmaceutical ingredient. Rege Nephro is currently conducting a Phase 2 trial of Tamibarotene for autosomal dominant polycystic kidney disease in Japan and plans to initiate U.S. trials after confirming efficacy and safety.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: StockTitan The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments